Ronald Berenson, MD, Co-founder, President and CEO, has been the architect of multiple entrepreneurial ventures in the biopharmaceutical industry. He was founder, board member, President and CEO of Xcyte Therapies, a NASDAQ-listed company that developed T-cell therapies for hematology and oncology indications. He was also founder, board member, Executive VP, Chief Medical Officer and Chief Scientific Officer for CellPro, a NASDAQ-listed company that developed and commercialized stem cell harvesting methodologies for hematology and oncology applications. He obtained his oncology training at Stanford University Medical Center, MD from Yale Medical School and BS from Stanford University.

Susan Perrine MD, Co-founder, Chief Scientific Officer and VP, Clinical Affairs, is a HemaQuest founder and co-principal inventor of the HemaQuest short chain fatty acid (SCFA) technology platform. Dr. Perrine was President and CSO of HemaQuest's predecessor company, Gene Regulation Laboratories, Inc. She is Professor of Medicine, Pediatrics, Pharmacology and Experimental Therapeutics at Boston University School of Medicine (BU). She is also Director of the Hemoglobinopathy Thalassemia Research Unit at the BU Cancer Research Center. She received her MD from Tufts, a Master's Degree from the Harvard School of Public Health, and completed her residency and sub-specialty training at Tufts Medical Center, Boston Children's Hospital, the Dana-Farber Cancer Institute, and Harvard Medical School.

Patrick Bobbitt, VP, Development, has over 17 years of experience in drug development at biotechnology and pharmaceutical companies where he has held roles of steadily increasing responsibility. He has served as Director of Clinical Operations for Seattle Genetics and Cell Therapeutics, Global Project Manager at ICOS Corporation and has experience coordinating successful pivotal trials and New Drug Applications in the US and in the EU. He has extensive prior experience with process chemistry, laboratory management and compliance. Mr. Bobbitt has a BS degree from Lamar University and is certified in Project Management from the Project Management Institute.

Elsa Johnson, MBA, PMP, Director, Project Management, brings 18 years of experience in business and drug development at large and small biopharmaceutical companies. Prior to HemaQuest, she served as Senior Project Manager at Nastech Pharmaceuticals and Corus Pharmaceuticals (later acquired by Gilead) where she led drug development teams in the planning and implementation of multiple lead candidates. She held project and clinical operations manager positions at PAREXEL International, a leading contract research organization. Ms. Johnson has a BS degree in Economics from Southern Methodist University, an MBA from the Lake Forest Graduate School of Business, and a certification from the Project Management Institute.

Raymond Calvert, Chief Financial Officer, provides financial leadership for the Company as a contract CFO. Mr. Calvert works with early stage, private life sciences and technology companies to provide financial oversight and leadership, including assistance with financing strategy, capital raising, and budgeting and forecasting. From 2001 to 2009, serving as CFO for Northstar Neuroscience, he directed financial and administrative operations, including raising venture and debt capital, and taking the Company public in May of 2006. Prior to Northstar, Mr. Calvert led the finance function for an early stage, venture backed ecommerce company, Altrec.com, and spent 10 years in the audit and assurance practice of Ernst & Young. He has a BA degree in Business Administration from the University of Washington.